Andrew Serafin J.D., M.B.A. Net Worth

The estimated Net Worth of Andrew Serafin is at least $1.99 Million dollars as of 2 December 2022. Mr Serafin owns over 38,000 units of Harmony Biosciences stock worth over $1,416,640 and over the last 4 years he sold HRMY stock worth over $0. In addition, he makes $570,919 as Exec. VP & Chief Strategy Officer at Harmony Biosciences.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr A HRMY stock SEC Form 4 insiders trading

Mr has made over 1 trades of the Harmony Biosciences stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 38,000 units of HRMY stock worth $312,360 on 2 December 2022.

The largest trade he's ever made was exercising 38,000 units of Harmony Biosciences stock on 2 December 2022 worth over $312,360. On average, Mr trades about 12,667 units every 0 days since 2020. As of 2 December 2022 he still owns at least 38,000 units of Harmony Biosciences stock.

You can see the complete history of Mr Serafin stock trades at the bottom of the page.

Mr. Andrew Serafin J.D., M.B.A. biography

Andrew Serafin J.D., M.B.A. is the Exec. VP & Chief Strategy Officer at Harmony Biosciences.

What is the salary of Mr A?

As the Exec. VP & Chief Strategy Officer of Harmony Biosciences, the total compensation of Mr A at Harmony Biosciences is $570,919. There are 3 executives at Harmony Biosciences getting paid more, with John Charles Jacobs M.B.A. having the highest compensation of $933,938.

How old is Mr A?

Mr A is 46, he's been the Exec. VP & Chief Strategy Officer of Harmony Biosciences since . There are 5 older and no younger executives at Harmony Biosciences. The oldest executive at Harmony Biosciences Holdings, Inc. is Dr. Jeffrey M. Dayno M.D., 64, who is the Chief Medical Officer.

Insiders trading at Harmony Biosciences

Over the last 4 years, insiders at Harmony Biosciences have traded over $224,163,932 worth of Harmony Biosciences stock and bought 514,681 units worth $12,537,009 . The most active insiders traders include Holdings A/S Novo, Andreas Wicki, and Antonio J. Gracias. On average, Harmony Biosciences executives and independent directors trade stock every 19 days with the average trade being worth of $2,907,691. The most recent stock trade was executed by Sandip Kapadia on 29 March 2024, trading 15,000 units of HRMY stock currently worth $559,200.

What does Harmony Biosciences do?

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Complete history of Mr Serafin stock trades at Harmony Biosciences

Harmony Biosciences executives and stock owners

Harmony Biosciences executives and other stock owners filed with the SEC include:

• John Charles Jacobs M.B.A.,
  Pres, CEO & Director
• Dr. Jeffrey M. Dayno M.D.,
  Chief Medical Officer
• Jeffrey Dierks M.B.A.,
  Exec. VP & Chief Commercial Officer
• Andrew Serafin J.D., M.B.A.,
  Exec. VP & Chief Strategy Officer
• Jeffrey S. Aronin,
  Founder & Non-Exec. Chairman
• Patricia L. Bank,
  Investor Relations Officer
• Nancy Leone,
  Head of Corp. Communications
• Tricia Glover,
  Chief Compliance Officer
• Christian Ulrich,
  Gen. Counsel
• Sharon Goldbach,
  Head of Facilities Operations & Exec. Admin.
• David Bradshaw,
  Head of Technical Operations
• Sandip S. Kapadia CPA, M.B.A.,
  Chief Financial Officer
• Holdings A/S Novo,
  10% owner
• Iv Pharma Holdings, Llc Val...,
  
• Fund Trust Ii Marshman,
  10% owner
• Andrew Serafin,
  CHIEF STRATEGY OFFICER
• Linda M Szyper,
  
• Antonio J. Gracias,
  
• R. Mark Graf,
  
• Eric L Motley,
  Director
• Jeffrey S Aronin,
  Director
• Jeffrey Dierks,
  CHIEF COMMERCIAL OFFICER
• John C Jacobs,
  PRESIDENT, CEO
• Jack Nielsen,
  
• Sandip Kapadia,
  CHIEF FINANCIAL OFFICER
• Jeffrey M. Dayno,
  PRESIDENT, CEO
• Gary Sender,
  
• Juan A. Sabater,
  
• Peter Anastasiou,
  
• Kumar Budur,
  CHIEF MEDICAL OFFICER